Investigational drug · Phase 3
PG4
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pneumococcal Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
7
Any phase or sponsor naming "PG4"
First trial start
2024
Jul 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PG4", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "PG4" as an intervention, largest first.
- A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to AdultsPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT07794748 · 4,701 participants · Start Sep 8, 2026 · Primary completion Apr 26, 2027
Drug: PG4 Multivalent Vaccine; PG4 Multivalent Vaccine and 2 more · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Lake Forest, California; Walnut Creek, California · 37 sites in all
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07629440 · 3,230 participants (planned) · Start May 29, 2026 · Primary completion Jun 5, 2029
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Fayetteville, Arkansas; Jonesboro, Arkansas · 134 sites in all
- A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07573462 · 2,400 participants (planned) · Start May 4, 2026 · Primary completion Dec 30, 2028
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Estero, Florida; Fort Lauderdale, Florida; Fort Myers, Florida · 91 sites in all
- Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and AdolescentsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07660198 · 1,200 participants (planned) · Start Jun 15, 2026 · Primary completion Dec 2, 2027
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Guntersville, Alabama; Fair Oaks, California · 77 sites in all
- A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06524414 · 605 participants · Start Jul 25, 2024 · Primary completion Mar 4, 2027
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) and 1 more · For: Pneumococcal Disease
Sites: Fayetteville, Arkansas; Jonesboro, Arkansas; La Puente, California · 67 sites in all
- A Study to Learn About How a New Pneumococcal Vaccine Works in AdultsPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT07086677 · 380 participants · Start Jul 22, 2025 · Primary completion Oct 21, 2027
Drug: PG4 vaccine in Buffer 1 with low dose PA-001; PG4 in Buffer 1 with low dose PA-002 and 5 more · For: Streptococcus Pneumoniae
Sites: Lake Forest, California; Rolling Hills Estates, California; Greenacres City, Florida · 20 sites in all
- A Study to Learn About How a New Pneumococcal Vaccine Works in ChildrenPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06531538 · 225 participants · Start Jul 30, 2024 · Primary completion Feb 9, 2026
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Washington D.C., District of Columbia; Miami, Florida; Chamblee, Georgia · 39 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CGGBP1-Regulated Heterogeneous C-T Transition Rates Correlate with G-quadruplex Potential of Terrestrial Vertebrate Genomes.
Kumar P, Singh U · J Mol Evol 2026
- Races of Puccinia graminis f. sp. avenae from 2023 to 2024 and Resistance of Oat Cultivars in China.
Gao Y, Zhang C, Zhang G, et al. · Plant Dis 2026
- Detangling knots: the intricate roles of G-quadruplexes in herpesvirus replication.
Lowery SA, Gordon SA, Paul A, et al. · J Virol 2026
- Pathogenesis of diffuse large B cell lymphoma proteogenotypes.
Enssle JC, Häupl B, Qoku A, et al. · Cancer Cell 2026
- Variation and selection at predicted G-quadruplexes across the human pangenome.
Mohanty SK, Marin MG, Smeds L, et al. · bioRxiv 2026
- Cumulative pregnancy and cumulative live birth rates and perinatal and obstetric outcomes in POSEIDON patients: insights from 19,371 IVF/ICSI cycles.
Wu D, Luo W, Li H, et al. · Arch Gynecol Obstet 2026
Also in development for Pneumococcal Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.